Drug Database
Back to search

France· FR:66607321

CABOMETYX 20 mg, comprimé pelliculé

A medicinal product containing (s)-malate de cabozantinib, registered in France by IPSEN PHARMA, on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedCABOMETYX 20 mg, comprimé pelliculéATC—REGISTER NO.FR:66607321PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about (s)-malate de cabozantinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
(S)-MALATE DE CABOZANTINIB
Manufacturer
IPSEN PHARMA
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930073520
    1 flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) avec sécurité enfant
    EUR 3.58

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

(s)-malate de cabozantinib in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All (s)-malate de cabozantinib products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Czechia · Cabozantinib Teva
  • Denmark · Cabozantinib Teva, Hasgobusno
  • Spain · Cabozantinib Sun
  • Finland · Cabozantinib Ratiopharm
  • Croatia · Kabozantinib Teva
  • Iceland · Cabometyx, Cometriq
  • Italy · Cabozantinib Teva
  • Liechtenstein · Cabometyx, Cometriq
  • Norway · Cabometyx, Cometriq

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/094c4bf9-e0a3-42d5-9175-6c4f2f64fc82
GET /v1/drugs/094c4bf9-e0a3-42d5-9175-6c4f2f64fc82?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66607321",
  "date_amm": "2016-09-09",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/16/1136",
  "substance": "(S)-MALATE DE CABOZANTINIB",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about (s)-malate de cabozantinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console